Polymeric Nanoparticle Delivery of Combination Therapy with Synergistic Effects in Ovarian Cancer
Treatment of ovarian cancer is challenging due to late stage diagnosis, acquired drug resistance mechanisms, and systemic toxicity of chemotherapeutic agents. Combination chemotherapy has the potential to enhance treatment efficacy by activation of multiple downstream pathways to overcome drug resis...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-04-01
|
| Series: | Nanomaterials |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-4991/11/4/1048 |
| _version_ | 1797537033404547072 |
|---|---|
| author | Shani L. Levit Christina Tang |
| author_facet | Shani L. Levit Christina Tang |
| author_sort | Shani L. Levit |
| collection | DOAJ |
| description | Treatment of ovarian cancer is challenging due to late stage diagnosis, acquired drug resistance mechanisms, and systemic toxicity of chemotherapeutic agents. Combination chemotherapy has the potential to enhance treatment efficacy by activation of multiple downstream pathways to overcome drug resistance and reducing required dosages. Sequence of delivery and the dosing schedule can further enhance treatment efficacy. Formulation of drug combinations into nanoparticles can further enhance treatment efficacy. Due to their versatility, polymer-based nanoparticles are an especially promising tool for clinical translation of combination therapies with tunable dosing schedules. We review polymer nanoparticle (e.g., micelles, dendrimers, and lipid nanoparticles) carriers of drug combinations formulated to treat ovarian cancer. In particular, the focus on this review is combinations of platinum and taxane agents (commonly used first line treatments for ovarian cancer) combined with other small molecule therapeutic agents. In vitro and in vivo drug potency are discussed with a focus on quantifiable synergistic effects. The effect of drug sequence and dosing schedule is examined. Computational approaches as a tool to predict synergistic drug combinations and dosing schedules as a tool for future nanoparticle design are also briefly discussed. |
| first_indexed | 2024-03-10T12:09:21Z |
| format | Article |
| id | doaj.art-1d5d78b74e67404f8251f9360911c491 |
| institution | Directory Open Access Journal |
| issn | 2079-4991 |
| language | English |
| last_indexed | 2024-03-10T12:09:21Z |
| publishDate | 2021-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Nanomaterials |
| spelling | doaj.art-1d5d78b74e67404f8251f9360911c4912023-11-21T16:16:55ZengMDPI AGNanomaterials2079-49912021-04-01114104810.3390/nano11041048Polymeric Nanoparticle Delivery of Combination Therapy with Synergistic Effects in Ovarian CancerShani L. Levit0Christina Tang1Chemical and Life Science Engineering Department, Virginia Commonwealth University, Richmond, VA 23284, USAChemical and Life Science Engineering Department, Virginia Commonwealth University, Richmond, VA 23284, USATreatment of ovarian cancer is challenging due to late stage diagnosis, acquired drug resistance mechanisms, and systemic toxicity of chemotherapeutic agents. Combination chemotherapy has the potential to enhance treatment efficacy by activation of multiple downstream pathways to overcome drug resistance and reducing required dosages. Sequence of delivery and the dosing schedule can further enhance treatment efficacy. Formulation of drug combinations into nanoparticles can further enhance treatment efficacy. Due to their versatility, polymer-based nanoparticles are an especially promising tool for clinical translation of combination therapies with tunable dosing schedules. We review polymer nanoparticle (e.g., micelles, dendrimers, and lipid nanoparticles) carriers of drug combinations formulated to treat ovarian cancer. In particular, the focus on this review is combinations of platinum and taxane agents (commonly used first line treatments for ovarian cancer) combined with other small molecule therapeutic agents. In vitro and in vivo drug potency are discussed with a focus on quantifiable synergistic effects. The effect of drug sequence and dosing schedule is examined. Computational approaches as a tool to predict synergistic drug combinations and dosing schedules as a tool for future nanoparticle design are also briefly discussed.https://www.mdpi.com/2079-4991/11/4/1048polymerdrug deliverycancercombination chemotherapynanocarriertherapeutic efficacy |
| spellingShingle | Shani L. Levit Christina Tang Polymeric Nanoparticle Delivery of Combination Therapy with Synergistic Effects in Ovarian Cancer Nanomaterials polymer drug delivery cancer combination chemotherapy nanocarrier therapeutic efficacy |
| title | Polymeric Nanoparticle Delivery of Combination Therapy with Synergistic Effects in Ovarian Cancer |
| title_full | Polymeric Nanoparticle Delivery of Combination Therapy with Synergistic Effects in Ovarian Cancer |
| title_fullStr | Polymeric Nanoparticle Delivery of Combination Therapy with Synergistic Effects in Ovarian Cancer |
| title_full_unstemmed | Polymeric Nanoparticle Delivery of Combination Therapy with Synergistic Effects in Ovarian Cancer |
| title_short | Polymeric Nanoparticle Delivery of Combination Therapy with Synergistic Effects in Ovarian Cancer |
| title_sort | polymeric nanoparticle delivery of combination therapy with synergistic effects in ovarian cancer |
| topic | polymer drug delivery cancer combination chemotherapy nanocarrier therapeutic efficacy |
| url | https://www.mdpi.com/2079-4991/11/4/1048 |
| work_keys_str_mv | AT shanillevit polymericnanoparticledeliveryofcombinationtherapywithsynergisticeffectsinovariancancer AT christinatang polymericnanoparticledeliveryofcombinationtherapywithsynergisticeffectsinovariancancer |